Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00061655" target="_blank" >RIV/00216224:14110/12:00061655 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x" target="_blank" >http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02819.x" target="_blank" >10.1111/j.1478-3231.2012.02819.x</a>

Result language

angličtina

Original language name

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Original language description

Background &amp; Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dosereduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FN - Epidemiology, infection diseases and clinical immunology

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Liver International

ISSN

1478-3223

e-ISSN

—

Volume of the periodical

32

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

1270-1277

UT code for WoS article

000307722000011

EID of the result in the Scopus database

—